Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>On Efficacy, Vivus Vs. Arena

On Efficacy, Vivus Vs. Arena

Healthcare Sector and Stocks Analysis from Seeking Alpha

Tue, 24 Jul 2012

By Rx Stocks : Some posters on Seeking Alpha have suggested Arena Pharmaceuticals, Inc. 's ( ARNA ) Lorcaserin ( Belviq ) is as effective as Vivus, Inc. 's ( VVUS ) Qsymia, especially the moderate dose of Qsymia (7.5 mg Phentermine/46 mg Topiramate), compared with Belviq 10 mg twice daily. That is ...

Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha

Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.